# Biomarker Directed Treatment in Metastatic Colorectal Cancer

> **NCT01703390** · PHASE2 · COMPLETED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 47 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** FOLFIRI + Cetuximab
- **DRUG:** modifiedFOLFOX6 + Cetuximab

## Key facts

- **NCT ID:** NCT01703390
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-04
- **Primary completion:** 2018-02-23
- **Final completion:** 2020-07-03
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703390, "Biomarker Directed Treatment in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01703390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*